KA
Kairos Pharma, Ltd.
KAPA · AMEX
$1.75 +1.16% (+$0.02)
1M +8.02%
Market Cap $5.35M
P/E Ratio -
Div. Yield -
ROE 98.77%
Bulios Fair Price
$1.44
17.7% downside
Current Price
$1.75
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KAPA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 1.28x
PEG N/A
P/E N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 130.27%
ROIC 143.93%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 11.98x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
50 /100
Moderate Profitable years 0
Beta 1.48x
EPS volatility 21.58%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KAPA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John S. Yu
Employees
4
Headquarters
Los Angeles
Upcoming events
13 NOV
Earnings
Upcoming earnings report